Role Overview
argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART (a first-in-class neonatal Fc receptor blocker approved for gMG, with potential across dozens of severe autoimmune diseases).
The Senior Director is a senior commercial leader accountable for:
• Maximizing growth of Vyvgart Hytrulo in CIDP (Chronic Inflammatory Demyelinating Polyneuropathy).
• Strategically preparing for and integrating the launch of Empa in MMN (Multifocal Motor Neuropathy) and subsequently CIDP.
• Working within a multi-indication therapeutic franchise.
This role sits on the CIDP Indication Strategy Team and JIST. It owns the patient commercial strategy across the portfolio, with primary responsibility for accelerating performance, expanding reach, and strengthening positioning of Vyvgart Hytrulo in CIDP. It also involves defining the dual-asset strategy and co-positioning framework with cross-functional partners.
Success requires balancing short-term revenue growth for Vyvgart Hytrulo with long-term CIDP-MMN portfolio strategy, shaping the market to expand category demand, and building a cohesive enterprise narrative that maximizes total franchise growth.
Key Responsibilities
I. Maximize Growth Trajectory and Peak Revenue of Vyvgart in CIDP (Primary)
• Lead the development and evolution of patient commercial strategy to maximize growth across CIDP and MMN.
• Identify and unlock growth levers across awareness, consideration, therapy initiation, persistence, and lifecycle management.
• Strengthen competitive positioning and reinforce differentiated value.
• Drive omnichannel optimization using rigorous performance analytics and agile measurement.
• Expand addressable market through targeted patient segment strategies and ecosystem partnerships.
• Partner closely with HCP, Market Access, Medical, Patient Support Services, and Patient Advocacy to remove friction points across the patient journey.
• Co-lead proactive competitive response planning and scenario modeling.
II. Architect Dual-Asset Co-Positioning Strategy
• Define clear roles, positioning, and treatment sequencing for Vyvgart and Empa across CIDP and MMN.
• Develop a franchise-level value narrative that clarifies differentiation while reinforcing complementary strengths.
• Prevent internal cannibalization through disciplined segmentation and treatment pathway strategy.
• Establish guardrails for patient engagement, messaging, targeting, and lifecycle investment decisions.
• Lead trade-off discussions to optimize enterprise value versus individual brand preference.
III. Shape the Market to Expand Total Franchise Value
• Drive market shaping initiatives that grow category awareness and demand.
• Lead disease awareness and unbranded education strategies to increase top-of-funnel volume.
• Identify structural barriers (e.g., diagnostic delay, access constraints, patient inertia) and design strategic interventions.
• Influence evidence generation priorities in partnership with Medical and Development.
• Anticipate competitive shifts and adapt ecosystem strategy.
IV. Launch Integration – Second Asset
• Co-develop Patient Commercial Strategy for Empa MMN launch, aligned to franchise strategy.
• Ensure Empa launch positioning complements and strengthens Vyvgart Hytrulo.
• Define sequencing, patient targeting, and differentiation strategy.
• Align US strategy with Global framework while advocating for market-specific needs.
V. Enterprise & Strategic Leadership
• Serve as a core strategic voice within the Indication Strategy Team.
• Shape portfolio priorities and resource allocation decisions.
• Provide executive-ready strategic recommendations supported by analytics and scenario modeling.
• Mentor high-performing patient marketing talent.
• Model enterprise mindset, cross-functional influence, and disciplined prioritization.
Core Competencies
• Enterprise Portfolio Optimization
• In-Market Growth Acceleration
• Patient Engagement & Commercial Strategy
• Dual-Asset Strategy & Lifecycle Planning
• Launch Excellence
• Market Shaping & Category Expansion
• Data-Driven Decision Making & Agile Optimization
• Executive Influence & Strategic Trade-Off Leadership
Qualifications
• 12–15+ years of biopharma commercial experience.
• Deep patient marketing expertise in specialty or rare disease markets preferred.
• Demonstrated success driving performance of an in-market brand.
• Launch experience required.
• Experience managing multi-asset or multi-indication portfolios strongly preferred.
• MBA or advanced degree preferred.
Compensation & Location
• Location: Boston, MA (US).
• Annual base salary range: $236,000 – $324,500 USD (plus short- and long-term incentives and comprehensive benefits). Actual pay depends on experience, skills, competencies, and internal equity.
• Full-time role.
This is a high-visibility leadership position focused on both in-market execution and future franchise building in the autoimmune space. The posting emphasizes an inclusive environment and equal opportunity employment.
If you need help tailoring a resume/cover letter to this role, comparing it to similar positions, or anything else (e.g., company research on argenx), just let me know! Note that job postings can close or evolve, so check the official argenx careers site or LinkedIn for the latest application details.